Core Viewpoint - The company, Saili Medical, anticipates a net loss attributable to shareholders of between -160 million RMB and -209 million RMB for the fiscal year 2025, indicating a reduction in losses compared to the previous year [1] Group 1: Financial Performance - The expected net loss for 2025 represents a decrease in losses by 49.2397 million RMB to 2.397 million RMB year-on-year [1] - The primary reason for the performance change is a decline in operating revenue [1] Group 2: Strategic Changes - The company is undergoing a strategic transformation, which includes the transfer of part of its controlling subsidiaries, resulting in these subsidiaries no longer being included in the consolidated financial statements [1] - The decision to not renew certain business contracts after their expiration has also contributed to the decline in operating revenue [1] Group 3: Research and Development - The company is increasing its investment in research and development within the smart medical field, which is impacting profitability due to higher R&D expenses [1]

Financial Performance - The company expects a net profit attributable to shareholders for 2025 to be between -160 million RMB and -209 million RMB, indicating a decrease in loss by 49.24 million RMB to 23.97 million RMB year-on-year [4]. - The expected net profit attributable to shareholders after deducting non-recurring gains and losses for 2025 is projected to be between -180 million RMB and -230 million RMB, reflecting an increase in loss by 44.92 million RMB to 94.92 million RMB year-on-year [5]. - The total profit for the previous year (2024) was -148.30 million RMB, with a net profit attributable to shareholders of -209.24 million RMB [7]. Strategic Transformation - The company is undergoing a strategic transformation, leading to a decline in operating revenue due to the transfer of certain subsidiaries and the lack of renewal for some business contracts [8]. - Increased R&D investment in the smart medical field has impacted profits, contributing to the expected losses [9]. Receivables and Asset Assessment - The company is actively working on collecting receivables but has faced extended payment cycles from some clients, leading to credit impairment losses [10]. - There is an ongoing assessment of goodwill, long-term equity investments, and other asset values, with results yet to be determined [11]. - The company has not identified any significant uncertainties that could affect the accuracy of the earnings forecast [12].

塞力医疗公告称，预计2025年度归属于上市公司股东的净利润为-1.6亿元到-2.09亿元，同比亏损减少 0.24亿-0.49亿元；扣非净利润为-1.8亿元到-2.3亿元，同比亏损增加0.45亿-0.95亿元。上年同期净利润 为-2.09亿元。业绩预亏主因是转让部分控股子公司、业务到期未续约及行业政策影响致营收下降，研 发投入增加，以及应收债权和商誉减值。目前商誉等资产价值评估结果未确定，最终财务数据以2025年 年报为准。 ...

截至2026年1月28日收盘，塞力医疗(603716)报收于23.29元，下跌4.71%，换手率7.5%，成交量15.76万 手，成交额3.74亿元。 当日关注点 股本股东变化股东增减持 1月28日塞力医疗发布公告《塞力医疗:关于持股5%以上股东减持股份结果公告》，其股东上海盎泽私 募基金管理有限公司-盎泽太盈六号私募证券投资基金于2025年12月12日至2026年1月28日间合计减持 150.0万股，占公司目前总股本的0.7137%，变动期间该股股价上涨12.4%，截止1月28日收盘报23.29 元。 交易信息汇总资金流向 1月28日主力资金净流出3796.6万元，占总成交额10.15%；游资资金净流出3348.73万元，占总成交额 8.95%；散户资金净流入7145.33万元，占总成交额19.1%。 大宗交易 1月28日塞力医疗发生1笔大宗交易，成交金额2200万元。 公司公告汇总关于持股5%以上股东减持股份结果公告 塞力斯医疗科技集团股份有限公司持股5%以上股东上海盎泽私募基金管理有限公司-盎泽太盈六号私募 证券投资基金，自2025年12月4日至2026年1月28日，通过集中竞价和大宗交易方式合计减持公 ...

Group 1: Nipah Virus Detection Products - Wanfu Biology announced the launch of "Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR Method)" to meet the demand for rapid and accurate testing [2] - Kehua Bio stated that its subsidiary has developed a Nipah virus detection kit to support key prevention and control points such as customs and disease control centers [3] - Zhijiang Biology emphasized the importance of early virus isolation and nucleic acid testing due to the non-specific symptoms in early-stage patients, offering a high-sensitivity detection kit [4] - Capbio has developed a Nipah virus detection kit, providing core technical support for global quarantine and disease control monitoring [4] - Shengxiang Biology offers a dual-platform solution for rapid and accurate detection of Nipah virus, with its detection kit already receiving EU CE certification [4] - Antu Biology provides rapid detection support through its fully automated nucleic acid purification and real-time fluorescent PCR analysis system [4] Group 2: Market Reactions and Clarifications - Some A-share companies clarified their positions, stating they do not have any business related to Nipah virus. Hualan Biological announced it has no vaccine products for Nipah virus [5] - Sely Medical confirmed it currently has no Nipah virus testing reagents or treatment drugs in reserve [6] - Other companies like Weixin Kang and CanSino also stated they do not have related products [7]

Group 1 - The core point of the article is that Shanghai Anze has completed a share reduction plan, decreasing its holdings in the company by approximately 3.09 million shares, which represents about 0.99% of the total share capital as of December 10, 2025 [1] - From December 4 to December 17, 2025, Shanghai Anze reduced its shares by approximately 2.09 million shares through centralized bidding, which is 0.99% of the total share capital [1] - On January 28, 2026, Shanghai Anze further reduced its holdings by 1 million shares through block trading, accounting for 0.48% of the total share capital as of January 20, 2026 [1] Group 2 - After the completion of the share reduction, Shanghai Anze holds approximately 9.01 million shares, which is 4.29% of the total share capital as of January 20, 2026 [1] - The share reduction plan has been fully implemented, indicating a strategic decision by Shanghai Anze regarding its investment in the company [1]

责任编辑：小浪快报 进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为2200万元。该股近5个交易日累计 下跌5.21%，主力资金合计净流出1.07亿元。 1月28日，塞力医疗（维权）收跌4.71%，收盘价为23.29元，发生1笔大宗交易，合计成交量100万股， 成交金额2200万元。 第1笔成交价格为22.00元，成交100.00万股，成交金额2,200.00万元，溢价率为-5.54%，买方营业部为方 正证券股份有限公司湖北分公司，卖方营业部为财通证券股份有限公司上海分公司。 ...

| 证券代码：603716 | 证券简称：塞力医疗 公告编号：2026-006 | | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | 关于持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 持股 5%以上股东的基本情况 减持计划实施前，上海盎泽私募基金管理有限公司-盎泽太盈六号私募证券 投资基金(以下简称"上海盎泽"）持有塞力斯医疗科技集团股份有限公司（以下 简称"公司"）12,100,399 股无限售条件流通股，占截至 2025 年 8 月 20 日（公 司总股本为 210,139,246 股)公司总股本的 5.76%。上述股份来源于公司控股股 东赛海（上海）健康科技有限公司协议转让后取得的股份。 减持计划的实施结果情况 2025 年 10 月 1 日，公司披露了《关于持股 5%以上股东减持股份计划公告》 （公告编号：2025-087），上海盎泽计划在公告披露日起 15 个交易日后的三个月 （即 2025 年 10 月 30 日至 2 ...

格隆汇1月28日丨塞力医疗（维权）(603716.SH)公布，截至2026年1月28日，上海盎泽已完成本次减持 计划，通过集中竞价交易和大宗交易的方式合计减持公司股份3,091,200股，占公司截至2026年1月20日 （总股本为210,199,126股)总股本的1.47%。本次减持完成后，上海盎泽剩余持有公司股份9,009,199股， 占公司截至2026年1月20日总股本的4.29%。 ...

南财智讯1月28日电，塞力医疗公告，公司持股5%以上股东上海盎泽私募基金管理有限公司-盎泽太盈 六号私募证券投资基金于2025年12月4日至2026年1月28日期间，通过集中竞价及大宗交易方式合计减持 公司股份3,091,200股，占公司截至2026年1月20日总股本210,199,126股的1.47%。本次减持计划已实施 完毕，减持后上海盎泽持有公司股份9,009,199股，占总股本的4.29%。 ...